Natera

YTD

ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).

CEO

Stephen Leonard Chapman

CEOStephen Leonard Chapman

Employees

6,140

Employees6,140

Headquarters

Austin, Texas

HeadquartersAustin, Texas

Founded

2003

Founded2003

Employees

6,140

Employees6,140

NTRA Key Statistics

Market cap

28.78B

Market cap28.78B

Price-Earnings ratio

-132.10

Price-Earnings ratio-132.10

Dividend yield

—

Dividend yield—

Average volume

1.10M

Average volume1.10M

High today

$209.39

High today$209.39

Low today

$199.54

Low today$199.54

Open price

$209.35

Open price$209.35

Volume

1.49M

Volume1.49M

52 Week high

$256.36

52 Week high$256.36

52 Week low

$131.81

52 Week low$131.81

Stock Snapshot

The current Natera(NTRA) stock price is $203.00, with a market capitalization of 28.78B. The stock trades at a price-to-earnings (P/E) ratio of -132.10.

On 2026-04-09, Natera(NTRA) stock traded between a low of $199.54 and a high of $209.39. Shares are currently priced at $203.00, which is +1.7% above the low and -3.1% below the high.

Natera(NTRA) shares are trading with a volume of 1.49M, against a daily average of 1.1M.

During the past year, Natera(NTRA) stock moved between $131.81 at its lowest and $256.36 at its peak.

NTRA News

Simply Wall St 2h

Court Win on MRD Patents and Royalties Might Change The Case For Investing In Natera

Natera recently received a favorable ruling from the U.S. District Court in Delaware, which upheld the validity of its three asserted MRD patents and granted a...

Seeking Alpha 16h

Natera awarded 30% ongoing royalty in MRD patent litigation

Natera (NTRA) on Thursday said the United States District Court for the District of Delaware has ordered an ongoing 30% royalty on certain post-injunction sales...

TipRanks 17h

Natera awarded 30% ongoing royalty for MRD-related patents

Natera (NTRA) provided an update on a recent decision issued by the U.S. District Court in the District of Delaware regarding Natera’s litigation with ArcherDx...

Analyst ratings

90%

of 21 ratings

Buy

90.5%

Hold

9.5%

Sell

More NTRA News

Simply Wall St 6d

Assessing Natera Valuation After New Signatera Breast Cancer Study Results

Advertisement Why the latest Signatera study matters for Natera (NTRA) shareholders Natera (NTRA) is back in focus after publishing new Clinical Cancer Resear...

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

TE Connectivity

Flowserve

Fluor

iShares MSCI Emerging Mar…

KLA

Linde plc

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.